Adaptive Biotechnologies (ADPT) Net Margin (2018 - 2026)
Adaptive Biotechnologies (ADPT) posted Net Margin of 74.79% for Q1 2026, down 271.27% sequentially from 20.14% in Q4 2025, and down 1772.0% YoY from 4.47% in Q1 2025.
Adaptive Biotechnologies (ADPT) Net Margin (2018 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported Net Margin for 9 years, with the latest figure at 74.79% in Q1 2026.
- Quarterly Net Margin fell 1772.0% year-over-year to 74.79% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 61.32% (up 1216.0% YoY) and the FY2025 annual result came in at 22.38%, up 6799.0% from the prior year.
- Net Margin slipped to 74.79% in Q1 2026 per ADPT's latest filing, from 20.14% in the prior quarter.
- Over five years, Net Margin peaked at 10.16% in Q3 2025 and troughed at 620.92% in Q2 2023.
- A 5-year average of 154.77% and a median of 107.08% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin jumped 75763 bps in 2022, then slumped 46934 bps in 2023.
- Over 5 years, Net Margin stood at 70.44% in 2022, then plunged by 115 bps to 151.73% in 2023, then soared by 57 bps to 65.32% in 2024, then surged by 69 bps to 20.14% in 2025, then tumbled by 271 bps to 74.79% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 74.79%, 20.14%, and 10.16% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 14.65% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 13.89% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 27.82% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 18.47% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 5.52% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -12.22% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 17.86% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 22.67% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 10.65% |
| 10 | Adaptive Biotechnologies | 3.80 Bn | 3.58 Bn | 52.17 Mn | -74.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.79% |
| Dec 31, 2025 | -20.14% |
| Sep 30, 2025 | 10.16% |
| Jun 30, 2025 | -209.34% |
| Mar 31, 2025 | -57.06% |
| Dec 31, 2024 | -65.32% |
| Sep 30, 2024 | -69.12% |
| Jun 30, 2024 | -107.08% |
| Mar 31, 2024 | -115.21% |
| Dec 31, 2023 | -151.73% |
| Sep 30, 2023 | -132.72% |
| Jun 30, 2023 | -620.92% |
| Mar 31, 2023 | -153.27% |
| Dec 31, 2022 | -70.44% |
| Sep 30, 2022 | -102.13% |
| Jun 30, 2022 | -151.58% |
| Mar 31, 2022 | -540.36% |
| Dec 31, 2021 | -168.88% |
| Sep 30, 2021 | -694.67% |
| Jun 30, 2021 | -909.22% |